Upstream Bio, Inc. to present new Phase 2 VIBRANT trial data for verekitug at EAACI2026

Upstream Bio, Inc. to present new Phase 2 VIBRANT trial data for verekitug at EAACI2026
Upstream Bio, Inc. reveals new CRSwNP data

Upstream Bio, Inc. will present additional analyses from the Phase 2 VIBRANT trial of its drug verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI2026 congress in Istanbul.

The presentation, scheduled for Sunday, June 14, will feature a responder analysis focusing on key measures of disease. Industry observers will closely watch for new clinical insights as the company shares results in Room Munich.

Upstream Bio previously released initial Phase 2 VIBRANT trial data on verekitug for CRSwNP with comorbid asthma at the ATS2026 conference. The company is also set to attend the Goldman Sachs Global Healthcare Conference in Miami, where it will host a fireside chat on June 10. These events underline the company's ongoing efforts to engage both clinical and investment communities.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.